Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker

By  

Current Pharmaceutical Design, Vol. 21, Iss. 26, 2015-01 ,pp. : 3797-3806

Bentham Science Publishers

Access to resources Recommend Favorite

Nicotinic Receptors and the Treatment of Attentional and Cognitive Deficits in Neuropsychiatric Disorders: Focus on the 7 Nicotinic Acetylcholine Receptor as a Promising Drug Target for Schizophrenia

By  

Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Central Nervous System Agents), Vol. 7, Iss. 4, 2007-12 ,pp. : 269-288

Bentham Science Publishers

Access to resources Recommend Favorite

The Importance of Nicotinic Acetylcholine Receptors in Schizophrenia, Bipolar Disorder and Tourette's Syndrome

By  

Current Drug Targets-CNS & Neurological Disorders, Vol. 1, Iss. 4, 2002-08 ,pp. : 433-442

Bentham Science Publishers

Access to resources Recommend Favorite

7 Nicotinic Acetylcholine Receptor as a Potential Therapeutic Target for Schizophrenia

By  

Current Pharmaceutical Design, Vol. 17, Iss. 2, 2011-01 ,pp. : 121-129

Bentham Science Publishers

Access to resources Recommend Favorite

Selective Activation of Muscarinic Acetylcholine Receptors for the Treatment of Schizophrenia

By  

Current Pharmaceutical Biotechnology, Vol. 13, Iss. 8, 2012-06 ,pp. : 1563-1571

Bentham Science Publishers

Access to resources Recommend Favorite